Balyasny Asset Management’s Edwards Lifesciences EW Stock Holding History

Balyasny Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-34,500	Closed	-$2.94M	–	3067
2025 Q4	$2.94M	Sell	34,500 -17,700	-34%	-$1.45M	﹤0.01%	1677
2025 Q3	$4.06M	Buy	52,200 +36,100	+224%	+$2.82M	0.01%	1464
2025 Q2	$1.26M	Sell	16,100 -6,200	-28%	-$462K	﹤0.01%	1957
2025 Q1	$1.62M	Buy	+22,300	New	+$1.6M	﹤0.01%	1805
2024 Q4	–	Sell	-12,100	Closed	-$798K	–	2890
2024 Q3	$798K	Buy	+12,100	New	+$879K	﹤0.01%	2052
2024 Q2	–	Sell	-24,700	Closed	-$2.36M	–	2716
2024 Q1	$2.36M	Buy	+24,700	New	+$2.07M	﹤0.01%	1490
2021 Q3	–	Sell	-8,000	Closed	-$829K	–	2081
2021 Q2	$829K	Buy	+8,000	New	+$754K	﹤0.01%	1373
2019 Q2	–	Sell	-120,000	Closed	-$7.65M	–	1546
2019 Q1	$7.65M	Buy	+120,000	New	+$6.85M	0.05%	462

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Balyasny Asset Management's EW Position: Q1 2026 in Review

Balyasny Asset Management reduced its Edwards Lifesciences (EW) stake by 99% in Q1 2026, selling an estimated $129M and leaving 9,998 shares worth $801K. The position accounts for ﹤0.01% of the portfolio, ranked #2166.

Balyasny Asset Management first reported a position in EW in Q2 2013 and has held it in 33 quarters since. The position peaked at $154M in Q1 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Balyasny Asset Management held 9,998 shares of Edwards Lifesciences worth $801K as of Q1 2026.
Balyasny Asset Management sold 1,564,393 Edwards Lifesciences shares in Q1 2026, an estimated $129M.
Edwards Lifesciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2166 holding.
Balyasny Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 33 quarters since.
Balyasny Asset Management's Edwards Lifesciences position peaked at $154M in Q1 2025.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.